Articles by Laura Bush - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Laura Bush

New Adventures

Biotech, and bioprocessing more specifically, is a great place to be. But it's time for a new adventure.
Dec 1, 2010

Biotech, and bioprocessing more specifically, is a great place to be. But it's time for a new adventure.

A Dizzying Course

China's regulators acknowledge the quality gap, and have a plan for steady improvement.
Nov 1, 2010

China's regulators acknowledge the quality gap, and have a plan for steady improvement.

The Role of Noncritical Process Parameters in Quality by Design

Industry and regulators disagree over noncritical parameters
Oct 1, 2010

Industry and regulators disagree over noncritical parameters.

Taking on the Challenges

Good leaders look beyond industry woes to focus on patients
Oct 1, 2010

Good leaders look beyond industry woes to focus on patients

Amgen Issues Epogen and Procrit Recall

Sep 24, 2010

Amgen has issued Epogen and Procrit recall.

Regulators, Industry Disagree Over Noncritical Process Parameters at CMC Forum

Sep 8, 2010

Regulators, Industry Disagree Over Noncritical Process Parameters at CMC Forum

Biosimilars, Part 3: Interchangeability

The third holy grail of biosimilars: interchangeability.
Sep 1, 2010

The third holy grail of biosimilars: interchangeability.

ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture

Aug 23, 2010

ImClone, a subsidiary of Eli Lilly, has closed a manufacturing facility at its site in Branchburg, NJ, as originally reported by MyCentralJersey.com and confirmed by BioPharm International.

Tug of War

Regulatory relief requires that regulators trust companies to know what they are doing, and to do it—consistently.
Aug 1, 2010

Regulatory relief requires that regulators trust companies to know what they are doing, and to do it—consistently.

ADVERTISEMENT

ADVERTISEMENT

Click here